De novo design of small cyclic peptide inhibitors from non-canonical amino acids by cofolding-guided search
Harteveld, Z.; Rigoldi, F.; Toniolo, C.; Granger, A.; Gensous, C.; Blum, T.; Jean-Baptiste, R.; Kobayashi, M.; Siegal, G.; Habeshian, S.; Tagmose, L.; Horlacher, O.
Show abstract
Cyclic peptides can engage targets beyond the reach of small molecules, but their discovery typically relies on libraries reused across targets, diversification around a known interaction motif, or computational methods limited to a handful of non-canonical building blocks. Here, we present nCycle-Forge, a simulated annealing framework that designs cyclic peptide binders by iteratively substituting building blocks and scoring each proposal by cofolding with the target. We designed, synthesized, and screened 1,472 cyclic peptides against the active-site pocket of Thrombin and the shallow p53-binding surface of MDM2 from the target sequence alone and without fixing binding mo-tifs. The library yielded chemically diverse hits against both targets in a single round without experimental optimization, with hit rates comparable to or up to 24-fold higher than in larger experimental libraries. Purified designs reached sub- to low-micromolar potency, with the best Thrombin inhibitor at Ki 0.14 M and the best MDM2 binder at EC50 2.4 M. Surface plasmon resonance confirmed direct binding, competition with or-thosteric inhibitors at both sites, and weaker binding under conditions expected to linearize the designs. nCycle-Forge requires no building block-specific parameterization, conformer generation, or retraining, and provides a target-focused route to functional cyclic peptides beyond the canonical amino acid alphabet.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors 96%
- A fluorescent probe enables the discovery of improved antagonists targeting the intracellular allosteric site of the chemokine receptor CCR7 95%
- A resource to enable chemical biology and drug discovery of WDR Proteins 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.